Results 41 to 50 of about 4,640 (210)

An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma

Expert Review of Anticancer Therapy
Introduction Tumor protein 53 gene (TP53) is the most frequently mutated gene in human cancers. TP53 mutation status may have prognostic value across malignancy types, and its use as a predictive biomarker is limited. Selinexor is a novel oral exportin 1
Robert L. Coleman, Pratheek Kalyanapu, C. Walker, I. Vergote   +3 more
semanticscholar   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma

Acta Pharmacologica Sinica
Selective nuclear export inhibitor selinexor (SEL) represents a promising therapeutic strategy for relapsed/refractory multiple myeloma (RRMM). But its mechanisms of action as well as factors that influence therapeutic responses have not been fully ...
Jun-Ying Wang, Meng-Ping Chen, Jingjing Jiang, Yike Wan, Xin Li, Yi-Wen Zhang, Yipeng Fang, Hong-Hui Huang, Zhao-yu Qin, Jian Hou   +9 more
semanticscholar   +1 more source

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response

Technology in Cancer Research & Treatment, 2023
Introduction: Mantle cell lymphoma (MCL) can be stratified into blastoid and classical subtypes based on morphological features, with the former subtype having a poorer prognosis.
Sheng Yuan MS, Wei Zuo MS, Tingting Liu MS, Huan Fu MS   +3 more
doaj   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine
Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response ...
O. Alhalabi, M. Gouda, D. Milton, Hassan Ahmed Momin, Bulent Yilmaz, B. Stephen, C. Ejezie, J. Moyers, S. Gurses, J. How, S. Fu, J. Rodon, D. Hong, S. Piha-Paul, V. Subbiah, Ecaterina Elena Dumbrava, D. Karp, Filip Janku, F. Meric-Bernstam, N. Tannir, A. Naing   +20 more
semanticscholar   +1 more source

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method

Pharmaceutics
Background/Objectives: Selinexor is a selective nuclear-export inhibitor approved for hematologic malignancies, characterized by extensive plasma protein binding (>95%). However, a validated analytical method to accurately measure the clinically relevant
Suhyun Lee, Seungwon Yang, Hyeonji Kim, Wang-Seob Shim, Eunseo Song, Seunghoon Han, Sung-Soo Park, Suein Choi, Sungpil Han, Sung Hwan Joo, Seok Jun Park, Beomjin Shin, Donghyun Kim, Hyeon Su Kim, Kyung-Tae Lee, Eun Kyoung Chung   +15 more
doaj   +1 more source

Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment

Cells
Despite the major advancements in the repertoire for multiple myeloma (MM) treatment, this disease remains a chronically progressive plasma cell malignancy. Drug resistance and high relapse rates complicate the extended treatment strategies. However, the
K. Tasbihi, Heiko Bruns
semanticscholar   +1 more source

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia

Hematology
Objectives Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear.
Chunli Xu, Dandan Wang, Ruiqi Chen, Xu Feng, Feng Cheng, Yu Chen   +5 more
doaj   +1 more source

Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug–Drug Interactions of Selinexor with Posaconazole in Rats

Drug Design, Development and Therapy, 2021
Chen-jian Zhou,1 Hui-jun Wang,2 Chun-yan Zhou,2 Chao-fan Li,2 Ming-Jia Zhu,2 Xiang-jun Qiu2 1Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, 325027, People’s Republic of China; 2School of Basic Medical Sciences, Henan University of ...
Zhou C, Wang H, Zhou C, Li C, Zhu MJ, Qiu X   +5 more
doaj